Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02286622
Other study ID # MP-104-CL-024
Secondary ID
Status Completed
Phase Phase 1
First received November 4, 2014
Last updated August 15, 2017
Start date December 2014
Est. completion date February 2015

Study information

Verified date August 2017
Source PTC Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized, open-label, single-dose study to compare the PK of 21 desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with ESRD to that of 8 healthy matched control subjects (age, body mass index [BMI], and gender).


Description:

This is a non-randomized, open-label, single-dose study to compare the PK of 21 desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with ESRD to that of 8 healthy matched control subjects (age, body mass index [BMI], and gender).

All subjects with ESRD will be on hemodialysis (HD). Dosing of deflazacort followed by PK evaluation of 21 desacetyl DFZ and, if data permits, deflazacort, will only be performed on a non-HD day.

On Day 1, that will be scheduled on a non-HD day for subjects with ESRD, a single oral dose of deflazacort will be administered followed by serial blood sampling for 24 hours to assess the PK of 21 desacetyl-DFZ, and, if data permits, deflazacort.

Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

Subjects will return to the Clinical Research Unit (CRU) 3 days (± 1 day) following study drug administration to determine if any adverse events (AEs) have occurred since the last study visit. Subjects who terminate the study early will be contacted if the Principal Investigator (PI) deems necessary.

A total of sixteen (16) adult male and female subjects will be enrolled. Renal Impaired Cohort: Eight (8) subjects with ESRD on HD. Healthy Match Control Cohort: Eight (8) healthy subjects with estimated creatinine clearance (CLcr) ≥ 90 mL/min. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the ESRD cohort.

Each subject will receive a single oral dose of 18 mg (3 X 6 mg tablets) deflazacort, following an overnight fast.

Study drug will be administered orally with approximately 240 mL of water.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date February 2015
Est. primary completion date February 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Continuous non-smokers or moderate smokers

- For a female of non-childbearing potential: must have undergone a sterilization procedures or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and FSH serum levels consistent with postmenopausal status

- A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days

- If male, must agree not to donate sperm from dosing until 90 days Subject with ESRD on Hemodialysis

- Adult male or female, 18 80 years of age

- BMI = 18.5 and = 40.0 kg/m2 - Subject is maintained on a stable regimen of HD at least 3 months Healthy Subject

- Healthy adult male and female subjects will be matched 1:1 to a specific subject in the ESRD cohort based upon age, BMI, and gender [1:1]. The following criteria should be fulfilled:

- 18 to 80 years of age. Age must be within ± 15 years of the matched subject's age in the ESRD cohort

- BMI = 18.5 and = 40.0 kg/m2. BMI must be within ± 15% of the matched subject's BMI in the ESRD cohort

- Has a CLcr = 90 mL/min

Exclusion Criteria:

- Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study

- History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds (e.g., steroids or their formulations including lactose and corn starh)

- History (within the last year prior to dosing) or presence of peptic ulcers

- History or presence of:

- Gastritis or esophagitis, diverticulitis, ulcerative colitis (if there is probability of impending perforation), abscess or pyogenic infections, or fresh intestinal anastomosis

- Previous corticoids-induced myopathy

- Ocular herpes simplex

- Symptomatic cardiomyopathy at screening

- Immunosuppression or other contraindications for corticosteroid treatment

- History of chronic systemic fungal or viral infections

- Galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption

- Osteoporosis

- Myasthenia gravis

- Epilepsy

- Idiopathic hypocalcuria

- Seated blood pressure is less than 90/40 mmHg or greater than 170/100 mmHg

- Seated heart rate is lower than 40 bpm or higher than 99 bpm

- QTcF interval is > 500 msec

- Has received any live or live-attenuated vaccine within 30 days

- Has received any immunosuppressive agents, coal tar, and/or radiation therapies within 30 days

- Has received injectable corticoids in the 12 weeks prior to dosing or any oral form of corticoids in 30 days

- Unable to refrain from or anticipates the use of:

- Any drug known to be moderate or strong inhibitors or inducers of cytochrome P450 (CYP) 3A or P-glycoprotein (P-gp) for 14 days or 28 days, respectively

- Any medication or substance which cannot be discontinued at least 14 days

- Female subjects of childbearing potential

- Female subjects who are pregnant or lactating

- Positive results at screening for HIV, HBsAg or HCV

- Has been on a diet incompatible with the on study diet within 28 days

- Donation of blood or significant blood loss within 56 days

- Plasma donation within 7 days

- Participation in another clinical trial within 28 days Subject with ESRD

- Is a regular user of any medication that would significantly alter glomerular filtration rate, e.g., cimetidine

- Has presence of a renal carcinoma or acute renal disease caused by infection or drug toxicity

- History of drug abuse within the past 2 years

- Has a positive urine/breath alcohol or urine/serum/saliva drug testing Normal Renal Function

- History or presence of alcoholism or drug abuse within the past 2 years

- Positive urine drug or urine/breath alcohol results

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Deflazacort
Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone

Locations

Country Name City State
United States University of Miami Division of Clinical Pharmacology Miami Florida
United States Orlando Clinical Research Center Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
PTC Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Renal impairment on the pharmacokinetics (PK) of deflazacort in subjects with end-stage renal disease including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration. Renal impairment on the pharmacokinetics (PK) of deflazacort in subjects with end-stage renal disease including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration. 1 day
Secondary Safety and tolerability of one dose of deflazacort in subjects with end stage renal disease as measured by capturing occurrence of adverse events. Safety and tolerability of one dose of deflazacort in subjects with end stage renal disease as measured by capturing occurrence of adverse events. 1 day
See also
  Status Clinical Trial Phase
Completed NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Phase 1
Completed NCT03284164 - Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex Phase 1
Completed NCT05992155 - A Study of TAK-279 in Adults With or Without Kidney Problems Phase 1
Completed NCT05004311 - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Phase 1
Completed NCT04963738 - A Study of JNJ-73763989 in Adult Participants With Renal Impairment Phase 1
Terminated NCT02508740 - Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Phase 1
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Terminated NCT00984113 - Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00750620 - A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00499187 - Fanconi Syndrome Due to ARVs in HIV-Infected Persons Phase 4
Completed NCT01331941 - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Phase 1
Completed NCT05489614 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment Phase 1
Completed NCT03259087 - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) Phase 1
Completed NCT05086107 - Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment Phase 1
Recruiting NCT05349851 - Bowel Cleansing With Renal Impairment
Completed NCT03660241 - A Renal Impairment Study for PF-04965842 Phase 1
Recruiting NCT06037031 - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function Phase 1
Completed NCT03289208 - Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment Phase 1
Completed NCT02942810 - To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment Phase 1